FIELD: chemistry.
SUBSTANCE: invention relates to a compound of general formula (I) or to its pharmacologically acceptable salt, where R1 is a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 alkoxy, C3-C6 cycloalkyl group, C1-C6 alkylcarbonyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, C3-C6 cycloalkenyl group, phenyl group, 5- or 6-membered aromatic heterocyclic group having 1-2 heteroatoms in the ring, independently selected from the group consisting of a nitrogen atom and a sulfur atom, or a 5- or 6-membered aliphatic heterocyclic group having an unsaturated bond in the ring portion and having 1 heteroatom in the ring, independently selected from the group consisting of a nitrogen atom and an oxygen atom, where a 5- or 6-membered aromatic heterocyclic group and 5- or 6-membered aliphatic heterocyclic group having an unsaturated bond in the part of the ring, each optionally has 1 substitute, independently selected from group A, described below, V is a single bond, C1-C6 alkylene group or oxy-C1-C6 alkylene group, R2 is C3-C6 cycloalkyl group, bicyclo-C5-C8 cycloalkyl group, a 5- or 6-membered aliphatic heterocyclic group having 1 or 2 heteroatoms in the ring, independently selected from the group consisting of a nitrogen atom and an oxygen atom, or a spiro-ring group containing two spiro-condensed rings independently selected from the group consisting of a 4–6 membered aliphatic heterocyclic ring having 1 nitrogen atom in the ring, and C3-C6 cycloalkyl ring, where C3-C6 cycloalkyl group, bicyclo-C5-C8 cycloalkyl group, a 5- or 6-membered aliphatic heterocyclic group and spiro-ring groups, each optionally having 1 substitute independently selected from group C described below, R3 is C1-C6 alkyl group, R4 is a halogen atom or C1-C6 alkyl group, R5 is C1-C6 alkyl group or C1-C6 alkoxygroup, R6 is C1-C6 alkyl group, group A consists of C1-C6 alkyl group and a 5- or 6-membered aliphatic heterocyclic group having 2 nitrogen atoms in the ring, where C1-C6 alkyl group and a 5- or 6-membered aliphatic heterocyclic group each optionally have 1 substituent independently selected from group B described below, group B consists of C1-C6 alkyl group and a 5- or 6-membered aliphatic heterocyclic group having 2 heteroatoms in the ring, independently selected from the group consisting of a nitrogen atom and an oxygen atom, and group C consists of C1-C6 alkyl group, C1-C6 alkylsulfonyl group, -NR20R21, C1-C6 alkoxy-C1-C6 alkyl group and di-C1-C6 alkylamino-C1-C6 alkyl group, where R20 and R21 each independently is a hydrogen atom, a formyl group or C1-C6 alkyl group. Also, the invention relates to a pharmaceutical composition for inhibiting EZH1 and/or EZH2 enzyme activity based on said compounds. 
(I).
EFFECT: obtained new compounds and pharmaceutical compositions based on them, which can be used in medicine for treatment of tumors.
18 cl, 3 tbl, 88 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2629118C2 |
| ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2632193C2 |
| TREATMENT METHOD | 2012 |
|
RU2621148C2 |
| SUBSTITUTED TRICYCLIC COMPOUNDS AND METHOD OF APPLICATION | 2016 |
|
RU2744766C2 |
| DISPIROPYRROLIDINE DERIVATIVES | 2012 |
|
RU2612534C2 |
| ANILIDES OF AMINO ACIDS AS LOW-MOLECULAR MODULATORS IL-17 | 2019 |
|
RU2815505C2 |
| SUBSTITUTED CHROMANS | 2015 |
|
RU2718060C2 |
| CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | 2008 |
|
RU2479584C2 |
| PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | 2015 |
|
RU2707953C2 |
